Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766997 | 0.88 | GPR84 (0.39) | CA1CA12CA9CA2EPHX1 | |
| SCHEMBL8766652 | 0.88 | GPR84 (0.39) | CA1CA12CA9CA2EPHX1 | |
| SCHEMBL21768139 | 0.80 | CES2 (0.39) | CA1CA2ZDHHC20MMP8MEN1 | |
| SCHEMBL8816793 | 0.77 | GPR84 (0.45) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL8767008 | 0.76 | GPR84 (0.50) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL8766674 | 0.76 | GPR84 (0.50) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL28762352 | 0.76 | CA1 (0.38) | CA1CA12CA9CA2EPHX1 | |
| SCHEMBL14341514 | 0.76 | CA1 (0.44) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL14341515 | 0.76 | CA1 (0.44) | CA1CA12CA9CA2ZDHHC20 | |
| SCHEMBL946188 | 0.75 | CA12 (0.47) | CA1CA12CA9CA2ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196772-A1 | NOVEL RNA BASE EDITING COMPOSITIONS, SYSTEMS, METHODS AND USES THEREOF | BEAM THERAPEUTICS INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230002760-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | EDITAS MEDICINE, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3796894-A1 | METHODS AND COMPOSITIONS FOR GENOME EDITING | Ligandal, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-112567032-A | Methods and compositions for genome editing | 利甘达尔股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112543650-A | Methods and compositions for genome editing | 利甘达尔股份有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002760-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | APOBEC3C, APOBEC3G, APOBEC3A | CA1 3733/4885CA12 3234/4885CA9 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.